Dabrafenib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma, Glioma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
US
  • BRAF V600E Mutation-Positive Metastatic NSCLC TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration (2.1)] .
    Outside this platform's coverage
  • BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options [see Dosage and Administration (2.1)] .
    Outside this platform's coverage
  • BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options [see Dosage and Administration (2.1)] . This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR) [see Clinical Studies (14.6)] . Continued approval for this indicati
Product first approved 2013FDA label
CN
  • In combination with trametinib for metastatic NSCLC with BRAF V600 mutation
Product first approved 2022baipharm.chemlinked.com
JP
  • Treatment of unresectable melanoma with BRAF mutation
Product first approved 2016PMDA
EU
  • Initial authorisation (BRAF V600 melanoma); the EPAR now also lists dabrafenib with trametinib for advanced BRAF V600 NSCLC
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (10)
Melanoma
NCT02224781 · National Cancer Institute (NCI)
2015-09-08 – 2026-12-19 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
What this study did
NCT02967692 · Novartis Pharmaceuticals
2017-02-17 – 2024-08-21 · Melanoma
What this study did
NCT03551626 · Novartis Pharmaceuticals
2018-08-29 – 2021-09-16 · Malignant Melanoma
What this study did
Other / comorbidity
NCT04940052 · Novartis Pharmaceuticals
2021-11-15 – 2027-05-25 · Differentiated Thyroid Cancer (DTC)
What this study did
NCT03784014 · Institut National de la Santé Et de la Recherche Médicale, France
2019-10-19 – 2026-01-20 · Soft Tissue Sarcoma
What this study did
NCT06264778 · Shandong University
2024-03-01 – 2025-12-31 · Ameloblastoma
What this study did
Phase 2/3 (3)
Glioma
NCT07440290 · Cancer Research UK
2026-04-01 – 2029-10 · Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Gastrointestinal Cancer, Non-Melanoma Skin Cancer (NMSC), Langerhans Cell Histiocytosis (LCH), Cancer, Erdheim-Chester Disease, Thyroid Carcinoma, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small Cell-Lung, Glioma, Multiple Myeloma, Thyroid Carcinoma, Anaplastic, Solid Tumour, Pancreatic Diseases
What this study did
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT06819605 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2025-03-01 – 2028-12-31 · Ameloblastoma
What this study did
Phase 2 (72)
Glioma
NCT07110246 · University of California, San Francisco
2025-11-07 – 2032-03-31 · BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
What this study did
NCT03919071 · National Cancer Institute (NCI)
2020-02-20 – 2027-09-30 · Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
What this study did
Melanoma
NCT03563729 · Inge Marie Svane
2018-06-06 – 2028-06-06 · Malignant Melanoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT02910700 · M.D. Anderson Cancer Center
2016-12-09 – 2027-12-08 · Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT02858921 · Melanoma Institute Australia
2017-11-08 – 2027-11 · Melanoma
What this study did
NCT02231775 · M.D. Anderson Cancer Center
2014-10-22 – 2027-04-01 · Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7
What this study did
NCT02196181 · National Cancer Institute (NCI)
2014-09-19 – 2027-03-15 · Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT03149029 · Massachusetts General Hospital
2017-11-27 – 2026-12-31 · Metastatic Melanoma
What this study did
NCT01972347 · Melanoma Institute Australia
2014-10-01 – 2026-06-16 · Melanoma
What this study did
NCT04310397 · M.D. Anderson Cancer Center
2020-01-29 – 2023-10-09 · Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
What this study did
NCT04059224 · Universitair Ziekenhuis Brussel
2019-01-28 – 2023-06-30 · Stage IV Melanoma, Stage III Melanoma
What this study did
NCT02083354 · Novartis Pharmaceuticals
2014-03-18 – 2021-04-19 · Cancer, Melanoma
What this study did
NCT03352947 · Cambridge University Hospitals NHS Foundation Trust
2017-11-03 – 2020-11-27 · Melanoma
What this study did
NCT01726738 · UNC Lineberger Comprehensive Cancer Center
2013-04-04 – 2020-09-17 · Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
What this study did
NCT02974803 · Canadian Cancer Trials Group
2018-02-09 – 2020-07-29 · Melanoma, Brain Metastases
What this study did
NCT03972046 · TriHealth Inc.
2019-06-24 – 2020-02-03 · Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
What this study did
NCT01682213 · Memorial Sloan Kettering Cancer Center
2012-09 – 2019-05 · Melanoma
What this study did
NCT02625337 · The Netherlands Cancer Institute
2016-01 – 2018-12 · Metastatic Melanoma
What this study did
NCT02410863 · Prof. Dr. med. Dirk Schadendorf
2015-11 – 2018-08 · Malignant Melanoma
What this study did
NCT02296996 · Universitair Ziekenhuis Brussel
2014-10 – 2017-12 · Malignant Melanoma
What this study did
NCT01978236 · GlaxoSmithKline
2014-04-08 – 2017-04-26 · Melanoma and Brain Metastases
What this study did
NCT01153763 · GlaxoSmithKline
2010-08-09 – 2016-06-01 · Melanoma
What this study did
NCT01721603 · University of California, San Francisco
2013-04 – 2016-01 · BRAFV600E Melanoma Patients
What this study did
NCT01701037 · Vanderbilt-Ingram Cancer Center
2013-01 – 2015-04 · Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
What this study did
NCT02052193 · University Hospital Tuebingen
2014-01 – 2014-12-15 · Metastatic Melanoma (Carrying BRAF V600 Mutation)
What this study did
Non-Small Cell Lung Cancer
NCT06563999 · Sun Yat-sen University
2024-11-01 – 2029-11-01 · Lung Cancer Stage III, Mutation
What this study did
NCT06054191 · Sun Yat-sen University
2024-02-01 – 2027-03-01 · NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
What this study did
NCT02672358 · Novartis Pharmaceuticals
2018-09-03 – 2020-12-07 · Non-Small-Cell Lung Cancer
What this study did
Other / comorbidity
NCT06119789 · Oslo University Hospital
2025-03-20 – 2036-08-01 · Rare Malignant Neoplasm
What this study did
NCT05159245 · Helsinki University Central Hospital
2021-12-10 – 2032-11-25 · Advanced Cancer, Solid Tumor, Haematological Malignancy
What this study did
NCT07022834 · West China Second University Hospital
2025-06-01 – 2030-06-01 · Langerhans Cell Histiocytosis (LCH)
What this study did
NCT06653517 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2023-01-01 – 2029-12-31 · Ameloblastoma, BRAF V600E Mutation Positive
What this study did
NCT07886905 · Washington University School of Medicine
2026-12-31 – 2029-05-13 · Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid Carcinoma
What this study did
NCT02693535 · American Society of Clinical Oncology
2016-03-14 – 2028-12-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT04675710 · M.D. Anderson Cancer Center
2021-06-24 – 2028-10-30 · Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma
What this study did
NCT06978400 · Blokhin's Russian Cancer Research Center
2025-03-01 – 2028-07-10 · Neoplasms
What this study did
NCT06967155 · Blokhin's Russian Cancer Research Center
2025-03-01 – 2028-06-10 · Neoplasms
What this study did
NCT07506109 · Tianjin Medical University Cancer Institute and Hospital
2026-03-01 – 2028-06 · BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable), Cetuximab, Dabrafenib, Ipilimumab N01
What this study did
NCT05525273 · Eva Marie Erfurth, MD, PhD
2023-09-01 – 2028-04-10 · Craniopharyngioma
What this study did
NCT06079333 · Leiden University Medical Center
2023-01-01 – 2028-01-01 · Anaplastic Thyroid Cancer
What this study did
Phase 1/2 (17)
Glioma
NCT06712875 · Ann & Robert H Lurie Children's Hospital of Chicago
2025-04-01 – 2029-06 · Low Grade Glioma, High Grade Glioma
What this study did
NCT04201457 · Pediatric Brain Tumor Consortium
2020-01-17 – 2026-12-31 · Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
What this study did
Melanoma
NCT01989585 · National Cancer Institute (NCI)
2014-03-24 – 2027-12-31 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
What this study did
NCT04557956 · National Cancer Institute (NCI)
2021-08-19 – 2027-03-11 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
What this study did
NCT02872259 · Haukeland University Hospital
2017-02-13 – 2024-05-23 · Melanoma
What this study did
NCT01902173 · National Cancer Institute (NCI)
2013-10-08 – 2023-12-23 · Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
What this study did
NCT03455764 · Dana-Farber Cancer Institute
2018-09-10 – 2023-09-05 · Melanoma
What this study did
NCT03754179 · Universitair Ziekenhuis Brussel
2018-01-23 – 2022-07-01 · Melanoma
What this study did
NCT02257424 · Abramson Cancer Center at Penn Medicine
2014-10 – 2021-10 · Advanced BRAF Mutant Melanoma
What this study did
NCT02130466 · Merck Sharp & Dohme LLC
2014-05-29 – 2021-07-14 · Melanoma, Solid Tumors
What this study did
NCT02392871 · Melanoma and Skin Cancer Trials Limited
2015-05 – 2020-04-17 · Metastatic Melanoma
What this study did
NCT03391050 · Aprea Therapeutics
2018-01-18 – 2018-08-08 · Melanoma
What this study did
NCT02143050 · University of Louisville
2014-09 – 2017-11-17 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT05585320 · Immuneering Corporation
2022-10-31 – 2028-06 · Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT01677741 · Novartis Pharmaceuticals
2013-05-23 – 2020-12-04 · Neoplasms, Brain
What this study did
NCT01750918 · Novartis Pharmaceuticals
2012-12-19 – 2020-06-18 · Cancer
What this study did
Phase 1 (36)
Melanoma
NCT04903119 · Rina Plattner
2022-06-01 – 2030-06-01 · Metastatic Melanoma, BRAF Gene Mutation
What this study did
NCT05388877 · Mayo Clinic
2022-10-20 – 2025-06-02 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Melanoma
What this study did
NCT03026517 · Memorial Sloan Kettering Cancer Center
2017-01 – 2025-01-21 · Melanoma
What this study did
NCT02097225 · National Cancer Institute (NCI)
2014-05-29 – 2022-10-26 · BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
What this study did
NCT01940809 · National Cancer Institute (NCI)
2013-08-28 – 2022-03-04 · BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
What this study did
NCT02382549 · Craig L Slingluff, Jr
2016-04 – 2022-02-28 · Melanoma
What this study did
NCT03332589 · Spirita Oncology, LLC
2018-07-02 – 2021-10-11 · Malignant Melanoma, Brain Metastases
What this study did
NCT03088176 · West Cancer Center
2017-06-25 – 2021-06-30 · Melanoma, BRAF Gene Mutation
What this study did
NCT03272464 · Massachusetts General Hospital
2019-05-29 – 2019-12-27 · Melanoma
What this study did
NCT02110355 · Kartos Therapeutics, Inc.
2014-12-19 – 2018-12-27 · Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
What this study did
NCT02027961 · MedImmune LLC
2013-12-20 – 2018-04-24 · Melanoma
What this study did
NCT02915666 · University of Texas Southwestern Medical Center
2016-10 – 2017-07-17 · Melanoma
What this study did
NCT02200562 · University of Utah
2014-12 – 2017-01-20 · Stage III or IV Melanoma
What this study did
NCT01767454 · GlaxoSmithKline
2013-02-12 – 2015-09-04 · Solid Tumours
What this study did
NCT02357732 · University of Pittsburgh
2015-08 – 2015-08 · Metastatic Melanoma
What this study did
Other / comorbidity
NCT03975231 · City of Hope Medical Center
2020-09-14 – 2027-10-05 · BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
What this study did
NCT01947023 · National Cancer Institute (NCI)
2013-09-27 – 2027-05-12 · Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
What this study did
NCT03091257 · Massachusetts General Hospital
2017-06-21 – 2026-09-15 · Multiple Myeloma
What this study did
NCT04418167 · JS InnoPharm, LLC
2020-06-18 – 2025-12-31 · Solid Tumors
What this study did
NCT04294160 · Novartis Pharmaceuticals
2020-07-22 – 2024-09-25 · BRAF V600 Colorectal Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02852239 · Novartis Pharmaceuticals
2016-12-19 – 2019-09-27 · Renal Impairment
What this study did
NCT02873650 · Novartis Pharmaceuticals
2016-12-20 – 2019-04-08 · Hepatic Impairment
What this study did
NCT01713972 · Manisha Shah
2012-11-19 – 2018-12-26 · Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT01231594 · Novartis Pharmaceuticals
2010-11-05 – 2018-04-09 · Cancer
What this study did
NCT02082665 · GlaxoSmithKline
2015-02-19 – 2016-08-01 · Cancer
What this study did
NCT01954043 · GlaxoSmithKline
2013-12-20 – 2016-02-29 · Cancer
What this study did
NCT01907802 · National Cancer Institute (NCI)
2013-08-23 – 2015-12-16 · BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
What this study did
NCT00880321 · GlaxoSmithKline
2009-06-04 – 2012-03-20 · Cancer
What this study did
Phase 4 (4)
Glioma
NCT03975829 · Novartis Pharmaceuticals
2019-11-04 – 2026-11-05 · Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood, Anaplastic Oligodendroglioma, Glioblastoma, Pilocytic Astrocytoma, Giant Cell Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Angiocentric Glioma, Chordoid Glioma of Third Ventricle, Gangliocytoma, Ganglioglioma, Anaplastic Ganglioglioma, Dysplastic Gangliocytoma of Cerebrellum, Desmoplastic Infantile Astrocytoma and Ganglioglioma, Papillary Glioneuronal Tumor, Rosette-forming Glioneuronal Tumor, Central Neurocytoma, Extraventricular Neurocytoma, Cerebellar Liponeurocytoma, Neurofibromatosis Type 1
What this study did
Non-Small Cell Lung Cancer
NCT03340506 · Novartis Pharmaceuticals
2018-01-26 – 2032-12-28 · Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
What this study did
Other / comorbidity
NCT07010393 · Fujian Medical University
2025-07-01 – 2028-12-31 · Thyroid Neoplasms
What this study did
NCT06195228 · Fudan University
2020-01-01 – 2028-12-31 · Advanced Thyroid Cancer Patients Who Received Target Therapy
What this study did
Early phase / not applicable (3)
Other / comorbidity
NCT05963087 · Zhejiang Cancer Hospital
2023-08 – 2026-06 · Advanced Colorectal Cancer
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT01534897 · Massachusetts General Hospital
2012-07 – 2014-03 · Papillary Thyroid Carcinoma
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Other / comorbidity
NCT06475989 · ECOG-ACRIN Cancer Research Group
2024-12-27 – 2030-09-30 · Refractory Differentiated Thyroid Gland Carcinoma
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Melanoma
NCT04527549 · ECOG-ACRIN Cancer Research Group
2021-06-01 – 2024-01-08 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
What this study did

Competitive landscape

This drug's own stage for Glioma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dabrafenib: this drugApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)not yet gradedNo reviewed efficacy summary in this indication
DordaviproneApprovedSmall moleculeMitochondrial caseinolytic protease P (ClpP), Dopamine D2 receptorWeak signalNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)Partial signal
NCT00626990: Overall survival: adjuvant temozolomide vs none, median 82.3 vs 46.9 months, hazard ratio 0.64 (95% CI 0.52 to 0.79), p<0.0001; concurrent temozolomide vs none, 66.9 vs 60.4 months, hazard ratio 0.97 (95% CI 0.73 to 1.28), p=0.76 (CT.gov posted results).
TovorafenibApprovedSmall moleculeKinase InhibitorWeak signalNo reviewed efficacy summary in this indication
TrametinibApprovedSmall moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
LuvometinibPhase 3Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
SafusidenibPhase 3Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
Abemaciclib (Verzenio)Phase 2Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
OlutasidenibPhase 2Small moleculeMutant IDH1not yet gradedNo reviewed efficacy summary in this indication
CrelosidenibPhase 1Small moleculeMutant IDH1 and IDH2not yet gradedNo reviewed efficacy summary in this indication
VebreltinibPhase 1Small moleculeMETnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(33 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dabrafenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Ameloblastoma, BRAF V600E Mutation PositiveRecruiting
Est. primary completion 2026-12-31 · NCT06653517 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 4Advanced Thyroid Cancer Patients Who Received Target TherapyRecruiting
Est. primary completion 2026-12-31 · NCT06195228 · CT.gov ↗
What to watch
2027 (18)
January 2027 (1)
Phase 2Anaplastic Thyroid CancerRecruiting
Est. primary completion 2027-01-01 · NCT06079333 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-03-15 · NCT02196181 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-04-01 · NCT02231775 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT05585320 · CT.gov ↗
What to watch
Phase 2Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation, BRAF Mutation-Related TumorsActive not recruiting
Est. primary completion 2027-06-20 · NCT04238624 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor …Active not recruiting
Est. primary completion 2027-09-02 · NCT04544111 · CT.gov ↗
What to watch
Phase 2CraniopharyngiomaRecruiting
Est. primary completion 2027-09-10 · NCT05525273 · CT.gov ↗
What to watch
Phase 2GliomaActive not recruiting
Est. primary completion 2027-09-30 · NCT03919071 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗
What to watch
Phase 2NeoplasmsRecruiting
Est. primary completion 2027-11-10 · NCT06978400 · CT.gov ↗
What to watch
Phase 2NeoplasmsActive not recruiting
Est. primary completion 2027-11-10 · NCT06967155 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2BRAF V600E, Colorectal Cancer, Sintilimab, MSS (Microsatellite Stable), Cetuximab, Dabrafenib, Ipilimumab N01Recruiting
Est. primary completion 2027-12 · NCT07506109 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 1/2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT01989585 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
2028 (5)
June 2028 (1)
Phase 2Langerhans Cell Histiocytosis (LCH)Recruiting
Est. primary completion 2028-06-01 · NCT07022834 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-10-30 · NCT04675710 · CT.gov ↗
What to watch
Phase 2/3AmeloblastomaNot yet recruiting
Est. primary completion 2028-10-30 · NCT06819605 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2GliomaRecruiting
Est. primary completion 2028-12 · NCT06712875 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 2Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid CarcinomaNot yet recruiting
Est. primary completion 2029-04-08 · NCT07886905 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
Phase 2/3GliomaRecruiting
Est. primary completion 2029-10 · NCT07440290 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 2GliomaRecruiting
Est. primary completion 2032-03-31 · NCT07110246 · CT.gov ↗
What to watch
December 2032 (1)
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-12-28 · NCT03340506 · CT.gov ↗
What to watch
2033 (1)
November 2033 (1)
Phase 2Rare Malignant NeoplasmRecruiting
Est. primary completion 2033-11-30 · NCT06119789 · CT.gov ↗
What to watch

See the full readout calendar ↗